MX389496B - Compuestos de benzodiazolio como inhibidores del canal de sodio epitelial (enac) - Google Patents

Compuestos de benzodiazolio como inhibidores del canal de sodio epitelial (enac)

Info

Publication number
MX389496B
MX389496B MX2019005934A MX2019005934A MX389496B MX 389496 B MX389496 B MX 389496B MX 2019005934 A MX2019005934 A MX 2019005934A MX 2019005934 A MX2019005934 A MX 2019005934A MX 389496 B MX389496 B MX 389496B
Authority
MX
Mexico
Prior art keywords
sup
enac
compounds
sodium channel
benzodiazolium
Prior art date
Application number
MX2019005934A
Other languages
English (en)
Other versions
MX2019005934A (es
Inventor
Clive Mccarthy
Duncan Alexander Hay
Jonathan David Hargrave
Naomi Went
Thomas Beauregard Schofield
Original Assignee
Enterprise Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enterprise Therapeutics Ltd filed Critical Enterprise Therapeutics Ltd
Publication of MX2019005934A publication Critical patent/MX2019005934A/es
Publication of MX389496B publication Critical patent/MX389496B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuestos de formula general (I)(ver formula) (I) en donde R1, R2, R3, R4, R5 y X son como se definen en la presente son inhibidores del canal de sodio epitelial (ENaC) y son utiles para el tratamiento o prevención de enfermedades y condiciones respiratorias, condiciones de la piel y condiciones oculares.
MX2019005934A 2016-11-22 2017-11-22 Compuestos de benzodiazolio como inhibidores del canal de sodio epitelial (enac) MX389496B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1619694.1A GB201619694D0 (en) 2016-11-22 2016-11-22 Compounds
PCT/GB2017/053499 WO2018096325A1 (en) 2016-11-22 2017-11-22 Benzodiazolium compounds as enac inhibitors

Publications (2)

Publication Number Publication Date
MX2019005934A MX2019005934A (es) 2019-11-12
MX389496B true MX389496B (es) 2025-03-20

Family

ID=57993838

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005934A MX389496B (es) 2016-11-22 2017-11-22 Compuestos de benzodiazolio como inhibidores del canal de sodio epitelial (enac)

Country Status (20)

Country Link
US (4) US10941149B2 (es)
EP (1) EP3544981B1 (es)
JP (1) JP6980014B2 (es)
KR (1) KR102517273B1 (es)
CN (1) CN110214141B (es)
AU (1) AU2017364308B2 (es)
CA (1) CA3043132A1 (es)
DK (1) DK3544981T3 (es)
EA (1) EA039607B1 (es)
ES (1) ES2890226T3 (es)
GB (1) GB201619694D0 (es)
HU (1) HUE055692T2 (es)
IL (1) IL266745B (es)
MA (1) MA46878A (es)
MX (1) MX389496B (es)
PL (1) PL3544981T3 (es)
PT (1) PT3544981T (es)
TW (1) TWI756305B (es)
WO (1) WO2018096325A1 (es)
ZA (1) ZA201902710B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201610854D0 (en) 2016-06-21 2016-08-03 Entpr Therapeutics Ltd Compounds
GB201619694D0 (en) 2016-11-22 2017-01-04 Entpr Therapeutics Ltd Compounds
GB201717051D0 (en) * 2017-10-17 2017-11-29 Enterprise Therapeutics Ltd Compounds
GB201801355D0 (en) 2018-01-26 2018-03-14 Enterprise Therapeutics Ltd Compounds
GB201808093D0 (en) * 2018-05-18 2018-07-04 Enterprise Therapeutics Ltd Compounds
GB201908453D0 (en) 2019-06-12 2019-07-24 Enterprise Therapeutics Ltd Compounds for treating respiratory disease
AU2020290049A1 (en) 2019-06-12 2022-02-03 Tmem16A Limited Compounds for treating respiratory disease
GB201910608D0 (en) 2019-07-24 2019-09-04 Enterprise Therapeutics Ltd Compounds
JP2023552638A (ja) 2020-12-11 2023-12-18 ティーエムイーエム１６エー リミテッド 呼吸器疾患を治療するためのベンゾイミダゾール誘導体
CN118852442A (zh) 2023-04-26 2024-10-29 上海麦科思生物医药有限公司 抗ptk7抗体及其用途
GB202406247D0 (en) 2024-05-03 2024-06-19 Enterprise Therapeutics Ltd Compounds and pharmaceutical compositions

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858614B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenolic guanidine sodium channel blockers
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US6903105B2 (en) 2003-02-19 2005-06-07 Parion Sciences, Inc. Sodium channel blockers
CA2534569A1 (en) 2003-08-18 2005-02-24 Parion Sciences, Inc. Cyclic pyrazinoylguanidine sodium channel blockers
US20050090505A1 (en) 2003-08-18 2005-04-28 Johnson Michael R. Methods of reducing risk of infection from pathogens
AU2004266704B2 (en) 2003-08-18 2012-02-23 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
AU2004271945A1 (en) 2003-08-18 2005-03-24 Parion Sciences, Inc. Aliphatic pyrazinoylguanidine sodium channel blockers
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
WO2005042497A2 (en) * 2003-10-28 2005-05-12 Vertex Pharmaceuticals, Incorporated Benzimidazoles useful as modulators of ion channels
US7399766B2 (en) 2004-08-18 2008-07-15 Parion Sciences, Inc. Soluble amide & ester pyrazinoylguanidine sodium channel blockers
CA2600570C (en) * 2005-03-14 2011-12-06 Transtech Pharma, Inc. Benzazole derivatives, compositions, and methods of use as .beta.-secretase inhibitors
US7807834B2 (en) 2005-08-03 2010-10-05 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
GB0526240D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
WO2008124491A1 (en) 2007-04-03 2008-10-16 Parion Sciences, Inc. Pyrazinoylguanidine compounds for use taste modulators
US8318935B2 (en) 2007-05-07 2012-11-27 Novartis Ag Organic compounds 75074
WO2009019506A1 (en) 2007-08-03 2009-02-12 Astrazeneca Ab Heterocyclyc sulfonamides having edg-1 antagonistic activity
EP2231280B1 (en) 2007-12-10 2016-08-10 Novartis AG Amiloride-like Pyrazine-carboxamides as ENaC blockers
EP2257296B1 (en) 2008-02-26 2014-05-07 Parion Sciences, Inc. Poly aromatic sodium channel blockers
CN102015662A (zh) 2008-05-13 2011-04-13 诺瓦提斯公司 3,5-二氨基-6-氯-吡嗪-2-甲酸衍生物和它们作为上皮钠通道阻断剂用于治疗气道疾病的用途
BRPI0915018A2 (pt) 2008-06-10 2015-10-27 Novartis Ag compostos orgânicos
WO2011028740A1 (en) 2009-09-03 2011-03-10 Glaxo Group Limited ENaC BLOCKERS
WO2011079087A1 (en) 2009-12-23 2011-06-30 Glaxo Group Limited Enac blockers
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
TW201204353A (en) * 2010-06-08 2012-02-01 Vertex Pharma Formulations of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
SI2773633T1 (sl) 2011-11-02 2017-11-30 Boehringer Ingelheim International Gmbh Heterociklične spojine, zdravila, ki vsebujejo te spojine, njihova uporaba in postopki za njihovo pripravo
US8859559B2 (en) 2011-12-20 2014-10-14 Boehringer Ingelheim International Gmbh Substituted pyrazines and their use in the treatment of disease
EA201990616A3 (ru) 2012-05-29 2019-12-30 Парион Сайэнс, Инк. Дендримероподобные аминоамиды, обладающие активностью блокаторов натриевых каналов, для лечения сухости глаз и других заболеваний слизистых оболочек
US8841309B2 (en) 2012-09-24 2014-09-23 Boehringer Ingelheim International Gmbh Substituted pyrazines and their use in the treatment of disease
CN105073717B (zh) 2012-12-17 2018-05-22 帕里昂科学公司 可用于治疗由黏膜水化不足造成的疾病的氯-吡嗪甲酰胺衍生物
CN108658876A (zh) 2012-12-17 2018-10-16 帕里昂科学公司 3,5-二氨基-6-氯-n-(n-(4-苯基丁基)甲脒基)吡嗪-2-甲酰胺化合物
ES2674665T3 (es) 2012-12-17 2018-07-03 Parion Sciences, Inc. Compuestos de 3,5-diamino-6-cloro-N-(N-(4-fenilbutilo)carbamimidoilo)-pirazina-2-carboxamida
EP2991981B1 (en) 2013-04-30 2017-03-01 Boehringer Ingelheim International GmbH Diaminopyrazine compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof
CN105518000B (zh) 2013-07-02 2018-09-14 加州生物医学研究所 用于治疗囊性纤维化的化合物
JP6449870B2 (ja) 2013-07-08 2019-01-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肺および気道の疾患を処置するための上皮性ナトリウムチャネルの阻害剤としてのアミロライド型化合物
EP3022197B1 (en) 2013-07-15 2017-09-06 Boehringer Ingelheim International GmbH Novel tetra- and pentasubstituted benzimidazolium compounds
JP6461134B2 (ja) 2013-07-15 2019-01-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ベンゾイミダゾリウム化合物
EP3022198B1 (en) 2013-07-15 2019-09-11 Boehringer Ingelheim International GmbH Novel 5-substituted benzimidazolium compounds
WO2015018754A1 (en) 2013-08-08 2015-02-12 Boehringer Ingelheim International Gmbh Novel pyrazine amide compounds
JP6667538B2 (ja) 2015-01-12 2020-03-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器系疾患の治療に有用な置換ベンズイミダゾリウム化合物
US10155749B2 (en) * 2015-01-12 2018-12-18 Boehringer Ingelheim International Gmbh Substituted benzimidazolium compounds useful in the treatment of respiratory diseases
WO2016113169A1 (en) 2015-01-12 2016-07-21 Boehringer Ingelheim International Gmbh Tetra- and pentasubstituted benzimidazolium compounds useful in the treatment of respiratory diseases
EP3245200B1 (en) 2015-01-12 2021-03-10 Boehringer Ingelheim International GmbH 2-(pyrazin-2-ylcarbonylaminomethyl)benzimidazolium compounds as epithelial sodium channel inhibitors
JP6620171B2 (ja) 2015-08-20 2019-12-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規縮環フェノキシアセトアミド
CN108135897B (zh) 2015-08-20 2021-07-27 勃林格殷格翰国际有限公司 稠合的苯甲酰胺
GB201610854D0 (en) * 2016-06-21 2016-08-03 Entpr Therapeutics Ltd Compounds
GB201619694D0 (en) * 2016-11-22 2017-01-04 Entpr Therapeutics Ltd Compounds

Also Published As

Publication number Publication date
IL266745A (en) 2019-07-31
US12371436B2 (en) 2025-07-29
US10941149B2 (en) 2021-03-09
KR20190084076A (ko) 2019-07-15
ES2890226T3 (es) 2022-01-18
TWI756305B (zh) 2022-03-01
KR102517273B1 (ko) 2023-04-03
WO2018096325A1 (en) 2018-05-31
PL3544981T3 (pl) 2021-12-20
US20210147432A1 (en) 2021-05-20
CA3043132A1 (en) 2018-05-31
GB201619694D0 (en) 2017-01-04
MA46878A (fr) 2019-10-02
JP2019535747A (ja) 2019-12-12
CN110214141A (zh) 2019-09-06
US20250304590A1 (en) 2025-10-02
NZ753048A (en) 2024-09-27
EP3544981A1 (en) 2019-10-02
BR112019009864A2 (pt) 2019-08-27
EA201991253A1 (ru) 2019-11-29
AU2017364308A1 (en) 2019-05-23
PT3544981T (pt) 2021-09-23
TW201833111A (zh) 2018-09-16
JP6980014B2 (ja) 2021-12-15
EA039607B1 (ru) 2022-02-16
AU2017364308B2 (en) 2021-03-11
DK3544981T3 (da) 2021-09-20
US20190315757A1 (en) 2019-10-17
MX2019005934A (es) 2019-11-12
CN110214141B (zh) 2022-05-31
IL266745B (en) 2021-12-01
US11739094B2 (en) 2023-08-29
ZA201902710B (en) 2021-10-27
EP3544981B1 (en) 2021-06-23
US20240067653A1 (en) 2024-02-29
HUE055692T2 (hu) 2021-12-28

Similar Documents

Publication Publication Date Title
MX389496B (es) Compuestos de benzodiazolio como inhibidores del canal de sodio epitelial (enac)
CY1125214T1 (el) Ενωσεις ν-((ετ)αρυλμεθυλ)-ετεροαρυλ-καρβοξαμιδιων ως αναστολεις καλλικρεϊνης πλασματος
CY1123810T1 (el) Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
ZA202001717B (en) Compounds, salts thereof and methods for treatment of diseases
MX2023005636A (es) Inhibidores de bcl6 derivados de bencimidazolona.
MX2020007265A (es) Derivados de rapamicina.
CR20200312A (es) Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1
MX392026B (es) Compuestos heterocíclicos como inmunomoduladores.
CY1123059T1 (el) Αναστολη του διαυλου ιοντων παροδικου δυναμικου του υποδοχεα α1
MX389513B (es) Compuestos heterocíclicos como inmunomoduladores.
MX375323B (es) Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos.
JOP20190193A1 (ar) ممركبات 2-أريل غير متجانس-3-أكسو-2، 3-ثنائي هيدرو بيريدازين-4-كربوكساميد لمعالجة السرطان
MX379459B (es) Inhibidores de bromodominios.
MX377916B (es) Compuestos 4-amino-imidazoquinolina.
MX379264B (es) Profarmacos de amidas de piridona utiles como moduladores de canales de sodio.
MX390302B (es) Oxiesteroles y metodos de uso de los mismos
MX2015011984A (es) Inhibidores de bromodominio de dihidro-pirrolopiridinona.
MY171945A (en) Compositions, formulations and methods for treating ocular diseases
EA201891644A1 (ru) Антибактериальные соединения и их применение
EA201990400A1 (ru) Соединения и композиции и их применение
MX387443B (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
CR20200214A (es) ALCOHOLES TERCIARIOS COMO INHIBIDORES DE PI3K-y
EA201692358A1 (ru) Производные изоиндолина для применения в лечении вирусной инфекции
UY37466A (es) N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa
MX385687B (es) Inhibidores de calicreína plasmática humana.